quinuclidines has been researched along with Benign Neoplasms in 96 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 23 (23.96) | 29.6817 |
| 2010's | 62 (64.58) | 24.3611 |
| 2020's | 11 (11.46) | 2.80 |
| Authors | Studies |
|---|---|
| Abrahmsén, L; Degtjarik, O; Diskin-Posner, Y; Golovenko, D; Rozenberg, H; Shakked, Z | 1 |
| Fukazawa, E; Harada, K; Ichimata, M; Kobayashi, T; Matsuyama, F; Nakano, Y | 1 |
| Ahrorov, A; Attar, EC; Awad, MM; Das, S; Dumbrava, EE; Furqan, M; Gallacher, PD; Gandhi, L; Gao, X; Ghosh, A; Hickman, D; Mahipal, A; Park, H; Shapiro, GI; Singh, P; Starr, J; Wennborg, A | 1 |
| Bailey, WL; Navari, RM; Nelson, WW; Shoaib, S; Singh, R; Zhang, W | 1 |
| Minotti, G | 1 |
| Faisal, A; Furqan, M; Mithani, A; Saleem, RSZ; Ullah, R; Zahra, R | 1 |
| Crown, J; Duffy, MJ; O'Grady, S; Synnott, NC | 1 |
| Abrahmsen, L; Behrenbruch, C; Bykov, VJN; Ceder, S; Cheteh, EH; Clemons, NJ; Corrales Benitez, M; Dawar, S; Eriksson, SE; Fujihara, KM; Grandin, M; Hollande, F; Li, X; Ramm, S; Simpson, KJ; Wiman, KG | 1 |
| Bruera, E; Gallagher, C; Hui, D; Javle, M; Kaseb, A; Liu, D; Maddi, R; Overman, M; Puac, V; Shelal, Z; Yennurajalingam, S | 1 |
| Fujisaki, H; Goto, H; Hara, J; Ishida, Y; Koga, Y; Koh, K; Kosaka, Y; Kumamoto, T; Matsumoto, K; Mochizuki, S; Suzuki, R; Yuza, Y | 1 |
| Barkate, H; Bhagat, S; Dattatreya, PS; Patil, S; Vaswani, B | 1 |
| Dupuis, LL; Flank, J; Freedman, J; Gibson, P; Holdsworth, MT; Madden, JR; Orsey, A; Patel, P; Phillips, R; Portwine, C; Robinson, PD; Sung, L; Thackray, J | 1 |
| Basharova, E; Kabickova, E; Kovács, G; Nicolas, P; Spinelli, T; Wachtel, A | 1 |
| Crown, J; Duffy, MJ; Synnott, NC | 1 |
| An, Y; Chen, T; Chen, Y; Dong, Y; Fu, L; Jin, B; Jin, F; Jin, X; Liu, J; Liu, Y; Luo, Y; Man, L; Qu, J; Qu, X; Shi, J; Sun, T; Teng, Y; Teng, Z; Wang, J; Wang, Z; Wen, F; Xie, X; Yu, P; Yuan, C; Zhang, J; Zhang, L; Zhang, X; Zhao, M; Zhou, L; Zhu, Z | 1 |
| Deng, X; Kong, XR; Li, CC; Liang, X; Peng, L; Tan, J; Wang, S; Yang, C; Zhang, J; Zhao, Z | 1 |
| Arai, T; Hashimoto, H; Iwasa, S; Minato, K; Nagashima, K; Nakao, M; Nakayama, T; Ohyanagi, F; Sakai, H; Shimada, Y; Suzuki, K; Takeda, K; Takiguchi, T; Terakado, H; Yamamoto, N; Yanai, T | 1 |
| Aapro, M; Chang, J; Chessari, S; Dechaphunkul, A; Feng, J; Jordan, K; Lanzarotti, C; Lu, S; Wang, D; Zhang, L | 1 |
| Boccia, R; Calcanes, G; Caruana, D; McBride, A; Mosier, M; Vacirca, J | 1 |
| Abrahmsen, LB; Green, JA; Von Euler, M | 1 |
| Barnes, E; Chan, S; Chow, E; Chung, H; DeAngelis, C; Drost, L; Ganesh, V; Pasetka, M; Pulenzas, N; Tsao, M; Wan, BA; Yee, C; Zaki, P; Zhang, L | 1 |
| Chiu, L; Chow, R; DeAngelis, C; Lam, H; Milakovic, M; Popovic, M; Tsao, M | 1 |
| Galoczová, M; Vojtěšek, B; Zatloukalová, P | 1 |
| Cartagena-Albertus, JC; Engel Manchado, J; Moise, A; Montoya Alonso, JA; Moya García, S | 1 |
| Fukui, T; Inui, N; Iwashima, A; Kanehara, M; Kubota, K; Kumagai, T; Minato, K; Morise, M; Saeki, T; Sugawara, S; Takeda, Y; Tamura, T; Yoshimori, K | 1 |
| Grunberg, SM; Rugo, HS; Slusher, B | 1 |
| Goto, H; Myojo, T; Osawa, H | 1 |
| Blazer, M; Mori-Vogt, S | 1 |
| Agustoni, F; Braud, FD; Celio, L; Dotti, K; Niger, M; Ricchini, F | 1 |
| Ballinari, G; Barbour, SY; Cox, D; Morrow, GR; Schwartzberg, L; Thorn, MD | 1 |
| Akashi, K; Arita, S; Ariyama, H; Baba, E; Komoda, M; Kumagai, H; Kusaba, H; Nagata, K; Nakano, M; Okumura, Y; Takaishi, S; Tamura, S; Uchida, M | 1 |
| Affronti, ML; Friedman, HS; Herndon, JE; Schlundt, S; Schneider, SM | 1 |
| Algarra, SM; Azanza, JR; Blanco Prieto, M; Campanero, MA; del Barrio, A; Gomez-Guiu, A; Guillén Grimá, F; Gurpide, A; Lopez-Picazo, JM; Perez-Gracia, JL; Sadaba, B | 1 |
| Goto, T; Hara, S; Ikari, Y; Ishitsuka, K; Katsuya, H; Masaki, M; Nakashima, Y; Ogata, K; Sato, E; Takamatsu, Y; Tamura, K; Tanaka, T | 1 |
| Balser, C; Borroni, ME; Bosnjak, SM; Gralla, RJ; Hontsa, A; Jordan, K; Rizzi, G; Rossi, G | 1 |
| Abe, M; Furuya, K; Hasegawa, K; Hirashima, Y; Itamochi, H; Ito, K; Kai, K; Kuritani, K; Matoda, M; Nasu, K; Otsuki, T; Sato, S; Takano, M; Takeshima, N; Terao, K; Tsubamoto, H | 1 |
| Guo, JX; Huang, XE; Liu, J; Liu, YC; Wei, W; Xiao, Y | 1 |
| Bonizzoni, E; Celio, L; Di Nicola, M; Gianni, AM; Magni, M; Mirabile, A | 1 |
| Boccia, R; Cooper, W; Gabrail, N; Gralla, RJ; O'Boyle, E; Raftopoulos, H | 1 |
| Brygger, L; Herrstedt, J | 1 |
| Aapro, M; Karthaus, M; Lorusso, V | 1 |
| Wang, SY; Yang, ZJ; Zhang, L | 1 |
| Navari, RM | 3 |
| Borroni, ME; Filippov, A; Grunberg, SM; Karthaus, M; Lorusso, V; Rizzi, G; Rossi, G; Singh-Arora, R; Tibor, C | 1 |
| Eto, K; Fukushima, H; Furuhata, T; Isobe, H; Iwanaga, I; Kawamoto, Y; Komatsu, Y; Kudo, M; Masuko, H; Minami, S; Miyagishima, T; Nakajima, J; Nakamura, M; Oba, K; Ohsaki, Y; Okita, K; Sasaki, K; Shibuya, H; Takahashi, Y; Tateyama, M; Yokoyama, R; Yuki, S | 1 |
| Boccia, R; Cooper, W; Gralla, RJ; O'Boyle, E; Raftopoulos, H | 1 |
| Kabanov, SN; Kalabanova, EA; Mitashok, IS; Storozhakova, AE; Svetitskaya, YV; Vladimirova, LY | 1 |
| Basharova, EV; Kabickova, E; Kovács, G; Nicolas, P; Spinelli, T; Wachtel, AE | 1 |
| Aapro, MS; Roeland, E; Schwartzberg, LS | 1 |
| Aapro, M; Gralla, RJ; Hesketh, PJ; Jordan, K; Palmas, M; Rizzi, G; Rossi, G | 1 |
| Hou, F; Le, Q; Li, H; Li, W; Liu, S; Shi, Q; Zheng, L; Zong, S | 1 |
| Liaw, CC; Wu, CE; Yang, CK | 1 |
| Herrstedt, J; Ruhlmann, CH | 1 |
| Arata, K; Azuma, K; Fujiwara, K; Goto, K; Hashimoto, H; Hayashi, T; Kogure, Y; Matsui, R; Nagase, S; Nakao, M; Nogami, N; Ohyanagi, F; Seki, N; Shimada, T; Shimada, Y; Suzuki, K; Takeda, K; Takiguchi, T; Yamamoto, N; Yamanaka, T | 1 |
| Aapro, M; Bondarenko, I; Borroni, ME; Cardona-Huerta, S; Hansen, V; Karthaus, M; Oprean, C; Rizzi, G; Rossi, G; Rugo, H; Sarosiek, T; Schwartzberg, L | 1 |
| Astara, G; Dessì, M; Lepori, S; Loi, C; Madeddu, C; Mantovani, G; Massa, E | 1 |
| Huang, Y; Liang, H; Liu, D; Liu, W; Si, X; Wang, L; Yu, Z; Zhang, H | 1 |
| Aogi, K; Inoue, K; Kitagawa, C; Mitsuhashi, S; Ogura, T; Saito, M; Sakai, H; Sekine, I; Yanagita, Y; Yoshizawa, H | 1 |
| Giampaglia, M; Lorusso, V; Perrone, T; Petrucelli, L; Saracino, V; Spedicato, A | 1 |
| Crooks, PA; Freeman, ML; Geng, L; Greco, S; Morré, DJ; Morré, DM; Rachakonda, G; Rogers, BE; Roti, JL; Salleng, KJ; Sasi, S; Sekhar, KR; Sonar, VN; Ye, F | 1 |
| Chen, Q; Huang, C; Huang, J; Lin, T; Pan, L; Shen, H; Tian, W; Wang, J; Wang, Z; Zhang, L; Zhang, S; Zhou, J | 1 |
| D'Amico, MR; De Simone, G; Loffredo, G; Migliorati, R; Parasole, R; Petruzziello, F; Poggi, V; Ripaldi, M; Zanotta, G | 1 |
| Botrel, TE; Clark, L; Clark, OA; Faleiros, E; Paladini, L; Pegoretti, B | 1 |
| Likun, Z; Tao, ZL; Xiang, J; Xin, D; Yi, B | 1 |
| Balu, S; Buchner, D; Craver, C; Gayle, J | 1 |
| Balu, S; Cox, D; Craver, C; Gayle, J; Morrow, G; Schwartzberg, L | 1 |
| Demirag, MK; Demircan, S; Erdem, D; Gonullu, G; Yucel, I | 1 |
| Aogi, K; Inoue, K; Katakami, N; Kuranami, M; Masuda, N; Mizutani, M; Sakai, H; Yanagita, Y; Yoshizawa, H | 1 |
| Gao, HF; Liang, Y; Wu, HY; Zhang, DS; Zhou, NN | 1 |
| Araz, M; Ata, OY; Dogan, U; Yavas, C; Yavas, G | 1 |
| Abernethy, AP; Rangwala, F; Zafar, SY | 1 |
| Giampaglia, M; Gnoni, A; Lorusso, V; Perrone, T; Petrucelli, L; Saracino, V | 1 |
| Li, RC; Qiu, H; Zheng, LJ | 1 |
| Lehmann, BD; Pietenpol, JA | 1 |
| Gray, SE; Nagy, CK; Navari, RM | 1 |
| Boccia, R; Franco-Gonzales, E; Grunberg, S; Rubenstein, E; Voisin, D | 1 |
| Nieuw Amerongen, AV; Veerman, EC | 1 |
| Cartmell, A; Charu, V; Eisenberg, P; Figueroa-Vadillo, J; Grunberg, S; Hajdenberg, J; Macciocchi, A; Zamora, R | 1 |
| Cornett, PA; Eisenberg, P; Macciocchi, A; MacKintosh, FR; Ritch, P | 1 |
| Scott, LJ; Siddiqui, MA | 1 |
| Rubenstein, EB | 1 |
| Olver, IN | 1 |
| Schwartzberg, L | 1 |
| Lipp, HP | 1 |
| Fatigoni, S; Roila, F | 1 |
| Padezanin, S | 1 |
| Cartmell, A; Charu, V; Ferguson, S; Ginkel, A; Grote, T; Hajdenberg, J | 1 |
| McNulty, R | 1 |
| Chowhan, N; Einhorn, LH; Hanna, NH; Johnson, CS; Loehrer, PJ; McClean, J; Navari, RM; Passik, SD; Vinson, J | 1 |
| Wilkes, G | 1 |
| Andel, J; Angleitner-Boubenizek, L; Bernhart, M; Busch, K; Gehmacher, O; Hernler, T; Kastner, U; Lanz-Veit, A; Petru, E; Pluschnigg, U; Polachova, J; Rohde, M; Schiller, L; Schramböck, R; Stangl, W; Steger, G; Thödtmann, R; Zabernigg, A | 1 |
24 review(s) available for quinuclidines and Benign Neoplasms
| Article | Year |
|---|---|
Targeting p53 for the treatment of cancer.
Topics: Aminoquinolines; Antineoplastic Agents; Cell Cycle Proteins; Humans; Neoplasms; para-Aminobenzoates; Protein Isoforms; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-mdm2; Pyrrolidines; Quinuclidines; Thiosemicarbazones; Tumor Suppressor Protein p53 | 2022 |
Guideline for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: A focused update.
Topics: Adolescent; Child; Child, Preschool; Female; Humans; Infant; Isoquinolines; Male; Nausea; Neoplasms; Palonosetron; Practice Guidelines as Topic; Quinuclidines; Serotonin Antagonists; Vomiting | 2017 |
Mutant p53 as a target for cancer treatment.
Topics: Antineoplastic Agents; Cell Line, Tumor; Genes, p53; Genetic Therapy; Humans; Molecular Targeted Therapy; Mutation; Neoplasms; Quinuclidines; Tumor Suppressor Protein p53 | 2017 |
Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Dexamethasone; Drug Combinations; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Palonosetron; Quinuclidines; Radiotherapy; Randomized Controlled Trials as Topic; Serotonin Antagonists; Vomiting | 2018 |
Prima-1 and APR-246 in Cancer Therapy.
Topics: Apoptosis; Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Humans; Neoplasms; Quinuclidines; Tumor Suppressor Protein p53 | 2018 |
Emerging treatments in chemotherapy-induced nausea and vomiting.
Topics: Allosteric Regulation; Antiemetics; Antineoplastic Agents; Humans; Isoquinolines; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Palonosetron; Pyridines; Quinuclidines; Receptors, Serotonin, 5-HT3; Serotonin; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2013 |
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting.
Topics: Antineoplastic Agents; Humans; Induction Chemotherapy; Isoquinolines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Vomiting | 2013 |
5-Hydroxytryptamine3 receptor antagonists and cardiac side effects.
Topics: Aged; Antiemetics; Antineoplastic Agents; Cardiovascular Diseases; Granisetron; Humans; Isoquinolines; Long QT Syndrome; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2014 |
Review of oral fixed-dose combination netupitant and palonosetron (NEPA) for the treatment of chemotherapy-induced nausea and vomiting.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Combinations; Drug Interactions; Humans; Isoquinolines; Nausea; Neoplasms; Palonosetron; Pyridines; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Treatment Outcome; Vomiting | 2015 |
Olanzapine for preventing nausea and vomiting induced by moderately and highly emetogenic chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Dexamethasone; Emetics; Humans; Isoquinolines; Morpholines; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Olanzapine; Palonosetron; Quinuclidines; Vomiting | 2014 |
Profile of netupitant/palonosetron (NEPA) fixed dose combination and its potential in the treatment of chemotherapy-induced nausea and vomiting (CINV).
Topics: Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Humans; Isoquinolines; Molecular Structure; Nausea; Neoplasms; Palonosetron; Pyridines; Quinuclidines; Vomiting | 2015 |
Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; Granisetron; Humans; Isoquinolines; Morpholines; Nausea; Neoplasms; Network Meta-Analysis; Ondansetron; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Spiro Compounds; Treatment Outcome; Vomiting | 2016 |
New treatments on the horizon for chemoradiotherapy-induced nausea and vomiting.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Drug Therapy, Combination; Humans; Isoquinolines; Morpholines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Receptors, Serotonin, 5-HT3; Vomiting | 2016 |
Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis.
Topics: Antiemetics; Antineoplastic Agents; Glucocorticoids; Humans; Isoquinolines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2011 |
Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer.
Topics: Antiemetics; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Isoquinolines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Risk Factors; Safety; Serotonin Receptor Agonists; Vomiting | 2010 |
A systematic review and meta-analysis of intravenous palonosetron in the prevention of chemotherapy-induced nausea and vomiting in adults.
Topics: Adult; Antiemetics; Antineoplastic Agents; Constipation; Dexamethasone; Headache; Humans; Infusions, Intravenous; Isoquinolines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Treatment Outcome; Vomiting | 2011 |
Gastrointestinal symptoms in cancer patients with advanced disease: new methodologies, insights, and a proposed approach.
Topics: Antiemetics; Antineoplastic Agents; Dexamethasone; Gastrointestinal Diseases; Granisetron; Humans; Isoquinolines; Nausea; Neoplasms; Palliative Care; Palonosetron; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting; Zingiber officinale | 2012 |
Targeting mutant p53 in human tumors.
Topics: Antineoplastic Agents; Disease-Free Survival; Female; Humans; Male; Molecular Targeted Therapy; Mutation; Neoplasms; Patient Safety; Quinuclidines; Risk Assessment; Sensitivity and Specificity; Signal Transduction; Survival Analysis; Treatment Outcome; Tumor Suppressor Protein p53 | 2012 |
Current therapies for xerostomia and salivary gland hypofunction associated with cancer therapies.
Topics: Acupuncture Therapy; Antineoplastic Agents; Chewing Gum; Diet; Flavoring Agents; Humans; Muscarinic Agonists; Neoplasms; Oral Hygiene; Palliative Care; Parasympathomimetics; Pilocarpine; Quinuclidines; Radiotherapy; Saliva; Salivary Glands; Thiophenes; Xerostomia | 2003 |
Palonosetron.
Topics: Antiemetics; Antineoplastic Agents; Humans; Injections, Intravenous; Isoquinolines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2004 |
Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Topics: Acute Disease; Adult; Aged; Antiemetics; Antineoplastic Agents; Clinical Trials as Topic; Cytochrome P-450 CYP2D6; Dexamethasone; Female; Half-Life; Humans; Indoles; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Ondansetron; Palonosetron; Protein Binding; Quinolizines; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vomiting | 2004 |
Update on anti-emetics for chemotherapy-induced emesis.
Topics: Administration, Oral; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Australia; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granisetron; Humans; Indoles; Isoquinolines; Male; Neoplasms; Ondansetron; Palonosetron; Patient Satisfaction; Prognosis; Quality of Life; Quinolizines; Quinuclidines; Treatment Outcome; Tropisetron; Vomiting | 2005 |
Chemotherapy-induced nausea and vomiting: state of the art in 2006.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Humans; Isoquinolines; Medical Oncology; Morpholines; Nausea; Neoplasms; Palonosetron; Quality of Life; Quinuclidines; Vomiting | 2006 |
New antiemetic drugs.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Drug Therapy, Combination; Humans; Isoquinolines; Medical Oncology; Morpholines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Receptors, Serotonin, 5-HT3; Serotonin Antagonists; Vomiting | 2006 |
41 trial(s) available for quinuclidines and Benign Neoplasms
| Article | Year |
|---|---|
Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Humans; Middle Aged; Neoplasms; Quinuclidines | 2022 |
Fixed-Dose Netupitant and Palonosetron for Chronic Nausea in Cancer Patients: A Double-Blind, Placebo Run-in Pilot Randomized Clinical Trial.
Topics: Antiemetics; Antineoplastic Agents; Double-Blind Method; Drug Combinations; Humans; Isoquinolines; Nausea; Neoplasms; Palonosetron; Pilot Projects; Pyridines; Quinuclidines; Vomiting | 2021 |
Phase III study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in pediatric patients.
Topics: Antiemetics; Antineoplastic Agents; Child; Dexamethasone; Double-Blind Method; Humans; Infant, Newborn; Isoquinolines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Vomiting | 2021 |
Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Humans; Infant; Infant, Newborn; Isoquinolines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2017 |
Efficacy of Thalidomide in Preventing Delayed Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Trial (CLOG1302 study).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Dexamethasone; Double-Blind Method; Doxorubicin; Epirubicin; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Thalidomide; Vomiting; Young Adult | 2017 |
Palonosetron is nonsuperior to ondansetron in acute phase but provides superior antiemetic control in delayed phase for pediatric patients administered highly emetogenic chemotherapy.
Topics: Adolescent; Antiemetics; Child; Child, Preschool; Dexamethasone; Double-Blind Method; Female; Humans; Infant; Infant, Newborn; Isoquinolines; Male; Nausea; Neoplasms; Ondansetron; Palonosetron; Prospective Studies; Quinuclidines; Vomiting | 2018 |
A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Cisplatin; Dexamethasone; Double-Blind Method; Female; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Neoplasms; Olanzapine; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2018 |
A randomized phase III study evaluating the efficacy of single-dose NEPA, a fixed antiemetic combination of netupitant and palonosetron, versus an aprepitant regimen for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving h
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Asia; Cisplatin; Dexamethasone; Double-Blind Method; Drug Combinations; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Pyridines; Quinuclidines; Vomiting | 2018 |
Assessment of the administration of maropitant and loperamide to dogs with cancer for the prevention and reduction of adverse effects associated with the administration of paclitaxel.
Topics: Animals; Antidiarrheals; Antiemetics; Antineoplastic Agents, Phytogenic; Diarrhea; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Loperamide; Male; Neoplasms; Paclitaxel; Quinuclidines; Random Allocation; Vomiting | 2019 |
Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Drug Combinations; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Pyridines; Quinuclidines; Treatment Outcome; Vomiting | 2019 |
Palonosetron plus dexamethasone in highly emetogenic chemotherapy: pooled data from two Phase III trials.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2013 |
Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV).
Topics: Antiemetics; Antineoplastic Agents; Double-Blind Method; Female; Granisetron; Humans; Indoles; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2014 |
Randomized pharmacokinetic study comparing subcutaneous and intravenous palonosetron in cancer patients treated with platinum based chemotherapy.
Topics: Administration, Intravenous; Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Injections, Subcutaneous; Isoquinolines; Male; Middle Aged; Neoplasms; Palonosetron; Platinum; Quinuclidines; Treatment Outcome; Vomiting | 2014 |
A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.
Topics: Antineoplastic Agents; Double-Blind Method; Drug Combinations; Humans; Isoquinolines; Nausea; Neoplasms; Palonosetron; Pyridines; Quinuclidines; Vomiting | 2014 |
Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trial.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Genital Neoplasms, Female; Humans; Isoquinolines; Middle Aged; Morpholines; Nausea; Neoplasms; Palonosetron; Prospective Studies; Quality of Life; Quinuclidines; Vomiting | 2014 |
Phase II study on EANI combined with hydrochloride palonosetron for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Carmustine; Cisplatin; Cyclophosphamide; Dacarbazine; Doxorubicin; Electric Stimulation Therapy; Epirubicin; Humans; Ifosfamide; Isoquinolines; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Vomiting; Young Adult | 2014 |
Evaluation of an every-other-day palonosetron schedule to control emesis in multiple-day high-dose chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Vomiting | 2014 |
Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately or highly emetogenic chemotherapy: results of a prospective, randomized, do
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations; Double-Blind Method; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Prospective Studies; Quinuclidines; Severity of Illness Index; Treatment Outcome; Vomiting | 2015 |
Efficacy and safety of oral palonosetron compared with IV palonosetron administered with dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with solid tumors receiving cisplatin-based highly emetogenic chemothe
Topics: Administration, Intravenous; Administration, Oral; Antiemetics; Cisplatin; Dexamethasone; Double-Blind Method; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Vomiting | 2015 |
Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Dexamethasone; Female; Humans; Irinotecan; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Palonosetron; Quality of Life; Quinuclidines; Serotonin Antagonists; Treatment Outcome | 2015 |
Slow-release granisetron (APF530) versus palonosetron for chemotherapy-induced nausea/vomiting: analysis by American Society of Clinical Oncology emetogenicity criteria.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2015 |
Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study.
Topics: Adolescent; Antiemetics; Antineoplastic Agents; Child; Child, Preschool; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Follow-Up Studies; Humans; Infant; Internationality; Isoquinolines; Male; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2016 |
Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2016 |
NEPA, a fixed oral combination of netupitant and palonosetron, improves control of chemotherapy-induced nausea and vomiting (CINV) over multiple cycles of chemotherapy: results of a randomized, double-blind, phase 3 trial versus oral palonosetron.
Topics: Adult; Anthracyclines; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Double-Blind Method; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Pyridines; Quinuclidines; Vomiting; Young Adult | 2017 |
Palonosetron plus dexamethasone effectively prevents acute and delayed chemotherapy-induced nausea and vomiting following highly or moderately emetogenic chemotherapy in pre-treated patients who have failed to respond to a previous antiemetic treatment: c
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Dexamethasone; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2009 |
The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: a phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial.
Topics: Adult; Antiemetics; Antineoplastic Agents; Asian People; China; Double-Blind Method; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2009 |
Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Topics: Adult; Antiemetics; Antineoplastic Agents; Dexamethasone; Double-Blind Method; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2009 |
Single dose of palonosetron plus dexamethasone to control nausea, vomiting and to warrant an adequate food intake in patients treated with highly emetogenic chemotherapy (HEC). Preliminary results.
Topics: Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Eating; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Prospective Studies; Quinuclidines; Serotonin Antagonists; Vomiting | 2009 |
Randomized, double-blind, crossover study of palonosetron compared with granisetron for the prevention of chemotherapy-induced nausea and vomiting in a Chinese population.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Asian People; China; Cross-Over Studies; Double-Blind Method; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Survival Rate; Treatment Outcome; Vomiting; Young Adult | 2011 |
Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Databases, Factual; Female; Follow-Up Studies; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Time Factors; Vomiting | 2011 |
Electrocardiographic findings of palonosetron in cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Blood Pressure; Electrocardiography; Female; Heart Rate; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Time Factors; Vomiting; Young Adult | 2012 |
A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy.
Topics: Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Treatment Outcome; Vomiting | 2012 |
Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Cisplatin; Constipation; Dexamethasone; Drug Administration Schedule; Drug Therapy, Combination; Fatigue; Female; Headache; Hiccup; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Palonosetron; Prospective Studies; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting; Young Adult | 2013 |
Antiemetic efficacy of single-dose palonosetron and dexamethasone in patients receiving multiple cycles of multiple day-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Prospective Studies; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2012 |
The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Benzodiazepines; Cisplatin; Cyclophosphamide; Dexamethasone; Double-Blind Method; Doxorubicin; Female; Humans; Isoquinolines; Male; Metoclopramide; Middle Aged; Morpholines; Nausea; Neoplasms; Olanzapine; Palonosetron; Quinuclidines; Vomiting | 2013 |
Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial.
Topics: Administration, Oral; Adult; Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Injections, Intravenous; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Treatment Outcome; Vomiting | 2013 |
Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
Topics: Adult; Aged; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Humans; Indoles; Infusions, Intravenous; Isoquinolines; Male; Middle Aged; Neoplasms; Palonosetron; Quinolizines; Quinuclidines; Severity of Illness Index; Treatment Outcome; Vomiting | 2003 |
Efficacy, safety and pharmacokinetics of palonosetron in patients receiving highly emetogenic cisplatin-based chemotherapy: a dose-ranging clinical study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Injections, Intravenous; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Vomiting | 2004 |
Palonosetron.
Topics: Antiemetics; Antineoplastic Agents; Humans; Injections, Intravenous; Isoquinolines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2004 |
Combination therapy for chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy: palonosetron, dexamethasone, and aprepitant.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Dexamethasone; Female; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2006 |
A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Benzodiazepines; Dexamethasone; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Olanzapine; Outcome Assessment, Health Care; Palonosetron; Quinuclidines; United States; Vomiting | 2007 |
32 other study(ies) available for quinuclidines and Benign Neoplasms
| Article | Year |
|---|---|
Structural basis of reactivation of oncogenic p53 mutants by a small molecule: methylene quinuclidinone (MQ).
Topics: Antineoplastic Agents; Aza Compounds; Bridged Bicyclo Compounds, Heterocyclic; Crystallography, X-Ray; Humans; Loss of Function Mutation; Neoplasms; Protein Domains; Quinuclidines; Recombinant Proteins; Tumor Suppressor Protein p53 | 2021 |
Evaluation of adverse events in small-breed dogs treated with maropitant and a single dose of doxorubicin.
Topics: Animals; Diarrhea; Dog Diseases; Dogs; Doxorubicin; Neoplasms; Neutropenia; Prospective Studies; Quinuclidines; Vomiting | 2022 |
Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Cisplatin; Delivery of Health Care; Gastrointestinal Agents; Humans; Nausea; Neoplasms; Palonosetron; Quinuclidines; Retrospective Studies; Treatment Outcome; Vomiting | 2023 |
All Eyes on Me, Please: Ocular Palonosetron for the Cancer Patient with Nausea and Vomiting.
Topics: Antineoplastic Agents; Dexamethasone; Humans; Nausea; Neoplasms; Palonosetron; Quinuclidines; Vomiting | 2023 |
A cell-based high-throughput screen identifies inhibitors that overcome P-glycoprotein (Pgp)-mediated multidrug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brefeldin A; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gene Expression Regulation, Neoplastic; High-Throughput Screening Assays; Humans; Hydrazines; Hydrazones; Neoplasms; Quinolines; Quinuclidines; Sulfonamides; Tyrphostins | 2020 |
A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death.
Topics: Cell Death; Cell Line, Tumor; Humans; Mutation; Neoplasms; Pharmaceutical Preparations; Quinuclidines; Sulfhydryl Compounds; Tumor Suppressor Protein p53 | 2021 |
The effectiveness of NEPA in the prevention of chemotherapy-induced nausea vomiting among chemo naive patients in an Indian setting.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Drug Combinations; Female; Humans; India; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Pyridines; Quinuclidines; Retrospective Studies; Treatment Outcome; Vomiting | 2021 |
Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Delayed-Action Preparations; Dexamethasone; Female; Fluid Therapy; Granisetron; Humans; Injections, Subcutaneous; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Practice Guidelines as Topic; Quinuclidines; Retrospective Studies; Serotonin Antagonists; Treatment Outcome; Vomiting | 2018 |
Restoration of conformation of mutant p53.
Topics: Alkylation; Aminoquinolines; Antineoplastic Agents; Apoptosis; Clinical Trials as Topic; Ellipticines; Humans; Mutation; Neoplasms; Protein Binding; Protein Interaction Domains and Motifs; Pyrazoles; Pyrroles; Quinuclidines; Structure-Activity Relationship; Thiosemicarbazones; Tumor Suppressor Protein p53 | 2018 |
A pilot study with palonosetron in the prophylaxis of radiation-induced nausea and vomiting.
Topics: Adult; Aged; Aged, 80 and over; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Pilot Projects; Quinuclidines; Radiotherapy; Serotonin Antagonists; Vomiting | 2018 |
[Comparison of antiemesis effects of granisetron, aprepitant and dexamethasone to palonosetron, aprepitant and dexamethasone in treatment of high-emetic risk chemotherapy-induced nausea and vomiting - a retrospective study for efficacy and safety in a sin
Topics: Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Dexamethasone; Drug Combinations; Female; Granisetron; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Retrospective Studies; Risk; Vomiting | 2013 |
Efficacy and safety of an increased-dose of dexamethasone in patients receiving fosaprepitant chemotherapy in Japan.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Aprepitant; Benzimidazoles; Dexamethasone; Drug Therapy, Combination; Female; Granisetron; Humans; Isoquinolines; Japan; Male; Middle Aged; Morpholines; Neoplasms; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin Antagonists; Vomiting | 2014 |
Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice.
Topics: Adult; Antiemetics; Antineoplastic Agents; Brain Neoplasms; Dexamethasone; Female; Glioblastoma; Humans; Isoquinolines; Male; Medication Adherence; Middle Aged; Nausea; Neoplasms; Palonosetron; Quality of Life; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Translational Research, Biomedical; Treatment Outcome; Vomiting | 2014 |
Safety and pharmacokinetic evaluation of repeated intravenous administration of palonosetron 0.75 mg in patients receiving highly or moderately emetogenic chemotherapy.
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Dexamethasone; Female; Humans; Injections, Intravenous; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin Antagonists; Vomiting | 2014 |
5-HT3 receptors as important mediators of nausea and vomiting due to chemotherapy.
Topics: Antiemetics; Antineoplastic Agents; Benzodiazepines; Dexamethasone; Half-Life; Humans; Isoquinolines; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Olanzapine; Palonosetron; Quality of Life; Quinuclidines; Receptors, Neurokinin-1; Receptors, Serotonin, 5-HT3; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2015 |
[Experience with the use of palonosetron (onicit) in patients with solid tumors receiving cytostatic therapy].
Topics: Antiemetics; Antineoplastic Agents; Humans; Isoquinolines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Severity of Illness Index; Treatment Outcome; Vomiting | 2015 |
Advances in the Management of Chemotherapy-Induced Nausea and Vomiting: New Data From Recent and Ongoing Trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Combinations; Humans; Isoquinolines; Nausea; Neoplasms; Practice Guidelines as Topic; Pyridines; Quality of Life; Quinuclidines; Treatment Outcome; Vomiting | 2015 |
Safety of an Oral Fixed Combination of Netupitant and Palonosetron (NEPA): Pooled Data From the Phase II/III Clinical Program.
Topics: Adult; Aged; Antiemetics; Biomarkers, Pharmacological; Dexamethasone; Drug Combinations; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Neurokinin-1 Receptor Antagonists; Pyridines; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2016 |
Combination of palonosetron, aprepitant, and dexamethasone as primary antiemetic prophylaxis for cisplatin-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antiemetics; Antineoplastic Agents; Aprepitant; Cisplatin; Dexamethasone; Drug Therapy, Combination; Female; Humans; Isoquinolines; Male; Middle Aged; Morpholines; Nausea; Neoplasms; Palonosetron; Quinuclidines; Treatment Outcome; Vomiting | 2016 |
Indolyl-quinuclidinols inhibit ENOX activity and endothelial cell morphogenesis while enhancing radiation-mediated control of tumor vasculature.
Topics: Cell Movement; Cell Shape; Cells, Cultured; Drug Evaluation, Preclinical; Endothelial Cells; Endothelium, Vascular; Humans; Indoles; Membrane Proteins; Neoplasms; Neovascularization, Pathologic; Protein Disulfide Reductase (Glutathione); Quinuclidines; Transcription Factors | 2009 |
Palonosetron to prevent nausea and vomiting in children undergoing BMT: efficacy and safety.
Topics: Adolescent; Antiemetics; Bone Marrow Transplantation; Child; Child, Preschool; Female; Humans; Infant; Isoquinolines; Male; Nausea; Neoplasms; Palonosetron; Quinuclidines; Retrospective Studies; Serotonin Antagonists; Vomiting | 2010 |
Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
Topics: Adolescent; Aged; Antiemetics; Antineoplastic Agents; Databases, Factual; Female; Follow-Up Studies; Humans; Isoquinolines; Male; Middle Aged; Multivariate Analysis; Nausea; Neoplasms; Outpatient Clinics, Hospital; Palonosetron; Quinuclidines; Regression Analysis; Retrospective Studies; Serotonin 5-HT3 Receptor Antagonists; Vomiting; Young Adult | 2011 |
Acute effect of palonosetron on electrocardiographic parameters in cancer patients: a prospective study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Electrocardiography; Heart Rate; Humans; Isoquinolines; Middle Aged; Nausea; Neoplasms; Palonosetron; Prospective Studies; Quinuclidines; Serotonin Antagonists; Vomiting; Young Adult | 2012 |
[Comparison of the effect of palonosetron versus tropisetron in prevention of vomiting in patients receiving high dose cisplatin-based chemotherapy].
Topics: Aged; Antiemetics; Antineoplastic Agents; Cisplatin; Eating; Female; Humans; Indoles; Isoquinolines; Male; Middle Aged; Neoplasms; Palonosetron; Quinuclidines; Tropisetron; Vomiting | 2012 |
5HT3-receptor antagonists as antiemetics in cancer.
Topics: Adult; Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Child; Granisetron; Humans; Indoles; Isoquinolines; Nausea; Neoplasms; Ondansetron; Palonosetron; Practice Guidelines as Topic; Quinolizines; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Tropisetron; Vomiting | 2005 |
New approaches to preventing xerostomia.
Topics: Amifostine; Cytoprotection; Humans; Muscarinic Agonists; Neoplasms; Pilocarpine; Quinuclidines; Radiation Injuries; Radiation-Protective Agents; Radiotherapy Dosage; Radiotherapy, Intensity-Modulated; Salivary Glands; Thiophenes; Xerostomia | 2006 |
[Achieving optimal antiemetic management].
Topics: Antiemetics; Clinical Trials as Topic; Drug Administration Schedule; Humans; Infusions, Intravenous; Isoquinolines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Vomiting | 2005 |
[Second generation of 5-HT3 antagonists].
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Humans; Isoquinolines; Male; Neoplasms; Palliative Care; Palonosetron; Quinuclidines; Vomiting | 2005 |
Applying new data to manage CINV: achieving optimal outcomes through a comprehensive care model.
Topics: Antiemetics; Antineoplastic Agents; Aprepitant; Comprehensive Health Care; Evidence-Based Medicine; Humans; Isoquinolines; Models, Organizational; Morpholines; Nausea; Neoplasms; Nurse's Role; Oncology Nursing; Palonosetron; Patient Care Team; Practice Guidelines as Topic; Quinuclidines; Total Quality Management; Vomiting | 2006 |
Are all 5-HT3 receptor antagonists the same?
Topics: Humans; Indoles; Isoquinolines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Randomized Controlled Trials as Topic; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Therapeutic Equivalency; Vomiting | 2007 |
Antiemetic agents.
Topics: Administration, Oral; Anorexia; Antiemetics; Antineoplastic Agents; Aprepitant; Asthenia; Constipation; Diarrhea; Drug Interactions; Dyspepsia; Fatigue; Fever; Granisetron; Headache; Hiccup; Humans; Indoles; Injections, Intravenous; Isoquinolines; Morpholines; Nausea; Neoplasms; Ondansetron; Palonosetron; Quinolizines; Quinuclidines; Vomiting | 2007 |
Early Austrian multicenter experience with palonosetron as antiemetic treatment for patients undergoing highly or moderately emetogenic chemotherapy.
Topics: Adult; Age Factors; Aged; Antiemetics; Antineoplastic Agents; Austria; Breast Neoplasms; Cancer Care Facilities; Female; Humans; Isoquinolines; Male; Middle Aged; Nausea; Neoplasms; Palonosetron; Practice Guidelines as Topic; Product Surveillance, Postmarketing; Quinuclidines; Serotonin 5-HT3 Receptor Antagonists; Serotonin Antagonists; Sex Factors; Surveys and Questionnaires; Time Factors; Vomiting | 2008 |